Several brokerages have updated their recommendations and price targets on shares of Tabula Rasa Healthcare (NASDAQ: TRHC) in the last few weeks:

  • 11/1/2017 – Tabula Rasa Healthcare is now covered by analysts at First Analysis. They set an “overweight” rating and a $41.00 price target on the stock.
  • 10/24/2017 – Tabula Rasa Healthcare had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $29.00 price target on the stock.
  • 10/19/2017 – Tabula Rasa Healthcare had its price target raised by analysts at Wells Fargo & Company from $21.00 to $27.00. They now have a “market perform” rating on the stock.
  • 10/17/2017 – Tabula Rasa Healthcare had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $30.00 price target on the stock, up previously from $22.00.
  • 10/11/2017 – Tabula Rasa Healthcare was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $31.00 price target on the stock. According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
  • 9/30/2017 – Tabula Rasa Healthcare was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 9/20/2017 – Tabula Rasa Healthcare had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $29.00 price target on the stock, up previously from $20.00.
  • 9/7/2017 – Tabula Rasa Healthcare was downgraded by analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating. They now have a $21.00 price target on the stock, up previously from $17.00.

Tabula Rasa Healthcare (NASDAQ:TRHC) last posted its quarterly earnings results on Monday, August 7th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $29.70 million for the quarter, compared to analysts’ expectations of $27.84 million. Tabula Rasa Healthcare had a negative net margin of 10.27% and a negative return on equity of 9.58%. The firm’s quarterly revenue was up 32.6% on a year-over-year basis.

In other Tabula Rasa Healthcare news, insider Orsula V. Knowlton sold 8,000 shares of the business’s stock in a transaction on Wednesday, October 18th. The shares were sold at an average price of $26.68, for a total transaction of $213,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 24,000 shares of company stock valued at $527,920. Company insiders own 45.80% of the company’s stock.

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Receive News & Ratings for Tabula Rasa Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc and related companies with MarketBeat.com's FREE daily email newsletter.